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Abstract 
The preparation and characterization of the compounds 4'-(pyrimidin-5-yl)-4,2':6',4''-
terpyridine (3) and 4'-(2-methylpyrimidin-5-yl)-4,2':6',4''-terpyridine (4) are described. 
Preferential coordination through the terminal pyridine donors of the typ domain is 
observed when 3 and 4 are treated with ZnCl2 or ZnI2. The 1-dimensional coordination 
polymers [{ZnCl2(3)}n], [{ZnI2(3)}n] and [{ZnI2(4).MeOH}n] have been structurally 
characterized by single crystal X-ray crystallography. [{ZnI2(3)}n] is helical and 
crystallizes with both P- and M-helices in the lattice; the packing of P- and M-chains 
involves discrete tetradecker π-stacking domains involving 4,2':6',4''-tpy units. The 
introduction of the 2-methyl substituent on going from 3 to 4 has only a small effect on 
the structure of [{ZnI2(L)}n]  (L = 3 or 4). The two coordination polymer chains assemble 
through face-to-face π-interactions into sheets with the pyrimidin5-yl units projecting 
outwards. The presence of the 2-methyl substituents in 4 forces the sheets in 
 2 
[{ZnI2(4).MeOH}n] further apart compared to those in [{ZnI2(3)}n], leading to the 
accommodation of MeOH molecules in cavities between the sheets. 
____________________________________________ 
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1. Introduction 
The use of 4,2':6',4''-terpyridine (4,2':6',4''-tpy) ligands as metal-binding domains for the 
assembly of coordination polymers is highly attractive and topical [1]. Of the three 
nitrogen donors in 4,2':6',4''-tpy, only the outer two typically bind metal ions leading to a 
divergent, V-shaped building block with well-defined directionality. The reaction of 
4,2':6',4''-tpy with ZnCl2 leads to a helical coordination polymer [{ZnCl2(4,2':6',4''-tpy )n]  
[2], and this structural motif persists in a range of [{ZnX2(4'-R-4,2':6',4''-tpy )}n ] 
polymers in which R is a tert-butyl [3], aryl [4,5] or 4-alkoxyphenyl [6] substituent. 
Coordinatively non-innocent 4'-R functionalities have the potential to extend the 
coordination assembly and examples include a closed metallocapsule when R = 4-pyridyl 
[7,8] and 2- or 3- dimensional networks when R = CO2H [9,10,11]. We have also recently 
illustrated the assembly of a 2D → 2D parallel interpenetrated array of (4,4) sheets by 
using a ditopic bis(4,2':6',4''-terpyridine) [12].  
 We have previously demonstrated that the 2,2':6',2''-tpy domain in ligand 1 
(Scheme 1) preferentially binds iron(II) or ruthenium(II) leaving the 5-pyrimidyl 
substituent as a pendant moiety in the discrete complex cations [Fe(1)2]2+ and [Ru(1)2]2+ 
[13]. Post-treatment of [Ru(1)2][PF6]2 with CuCl2.2H2O results in the assembly of a 2-
dimensional network with copper(II) centres coordinated to the pyrimidinyl N-donors 
[13]. Recently, Granifo et al [14] have reported the synthesis of ligand 2 and shown that it 
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reacts with Zn(acac)2 (Hacac = acetylacetone) to give the discrete complex 
[Zn(acac)2(2)2], in addition to the 1-dimensional coordination polymer [{Zn(acac)2(2)}n]. 
In [Zn(acac)2(2)2], each ligand 2 is monodentate and binds through one pyridyl unit, 
while in [{Zn(acac)2(2)}n], each molecule of 2 bridges two zinc(II) centres and 
coordinates through the nitrogen donors of one pyridyl and one pyrimidinyl unit. These 
results contrast with our own observations on the coordination behaviour of ligands 3 and 
4, described in this work. 
 
Scheme 1. Ligand structures and atom numbering for NMR spectroscopic assignments. 
 
2. Experimental 
2.1  General  
1H and 13C NMR spectra were recorded on a Bruker Avance III-500 spectrometer with 
chemical shifts referenced to residual solvent peaks	(∂(TMS) = 0 ppm). Solution 
electronic absorption spectra were recorded on a Cary 5000 spectrophotometer. 
Electrospray ionization (ESI) mass spectra were recorded on a Bruker esquire 3000plus 
mass spectrometer.   
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 Pyrimidine-5-carbaldehyde (Alfa Aesar) and 2-methylpyrimidine-5-carbaldehyde 
(Fluorochem) were used as received.  	
2.2 Ligand 3 
Pyrimidine-5-carbaldehyde (0.28 g, 2.5 mmol) was dissolved in EtOH (40 mL) and 4-
acetylpyridine (0.57 mL, 0.62 g, 5 mmol) was added, followed by crushed KOH (0.28 g, 
5 mmol). The initially colorless solution changed to yellow and then red. Aqueous NH3 
(25% in water, 12.3 mL, 80 mmol) was added dropwise and the reaction mixture stirred 
at room temperature overnight. A yellow precipitate formed which was collected by 
filtration, washed with water (3 × 5 mL) and EtOH (3 × 5 mL) and recrystallized from 
CHCl3/MeOH. Compound 3 was obtained as a yellow solid (0.34 g, 1.28 mmol, 51%). 
Decomp. > 260 °C. 1H NMR (500 MHz, CDCl3) ∂ / ppm 9.39 (s, 1H, HC2) 9.13 (s, 2H, 
HC4), 8.83 (m, 4H, HA2), 8.09 (m, 4H, HA3), 8.04 (s, 2H, HB3). 1H NMR (500 MHz, d-
TFA) ∂ / ppm 9.97 (s, 2H, HC4) 9.80 (s, 1H, HC2), 9.06–8.90 (m, 8H, HA2/HA3), 8.83 (s, 
2H, HB3); 13C{1H} NMR (126 MHz, d-TFA) ∂ / ppm 158.4 (CC3), 157.0 (CA4), 155.2 
(CB2), 154.5 (CC2), 145.0 (CB4), 144.1 (CA2), 135.8 (CC5), 127.3 (CA3), 125.5 (CB3); IR 
(solid, ν / cm–1) 4696 (m), 3033 (w), 2925 (w), 1652 (w), 1613 (w), 1596 (s), 1569 (s), 
1553 (s), 1544 (m), 1539 (m), 1533 (m), 1506 (w), 1436 (s), 1416 (m), 1393 (s), 1356 
(m), 1327 (w), 1318 (w), 1274 (w), 1189 (m), 1133 (w), 1059 (w), 1029 (w), 995 (m), 
897 (w), 890 (w), 841 (m), 823 (s), 804 (w), 722 (s), 701 (m), 642 (m), 638 (s), 625 (s), 
619 (s), 616 (s), 609 (m), 514 (m), 508 (s), 502 (s). UV-VIS (CH2Cl2, 2.5 × 10–5 M) λ/nm 
(ε/ dm3 mol–1 cm–1) 242 (47359), 312 (9184). ESI MS m/z 312.2 [M+H]+ (calc. 312.1). 
Satisfactory elemental analysis could not be obtained (see text). 
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2.3 Ligand 4 
2-Methylpyrimidine-5-carbaldehyde (0.27 g, 2.21 mmol) was dissolved in EtOH (40 
mL), and 4-acetylpyridine (0.57 mL, 0.62 g, 5 mmol) was added followed by crushed 
solid KOH (0.33 g, 5.90 mmol) after which the solution turned red. Aqueous NH3 (25% 
in water, 13.9 mL, 90 mmol) was added dropwise and the mixture stirred overnight at 
ambient temperature. A yellow precipitate formed which was separated by filtration, 
washed with water (3 × 7 mL) and ethanol (3 × 7 mL) and recrystallized from 
chloroform/methanol. Compound 4 was obtained as a white solid (0.26 g, 0.78 mmol, 
32%). Decomposition > 260 °C. 1H NMR (500 MHz, CDCl3) ∂ / ppm 9.02 (s, 2H, HC4), 
8.83 (m, 4H, HA2), 8.09 (m, 4H, HA3), 8.01 (s, 2H, HB3), 2.87 (s, 3H, HMe); 13C{1H} NMR 
(126 MHz, CDCl3) ∂ / ppm 169.3 (CC2), 155.9 (CA4), 155.14 (CC4), 150.8 (CB4) 150.7 
(CA2), 145.3 (CB2), 128.5 (CC5), 121.1 (CA3), 118.3 (CB3), 25.9 (CMe); IR (solid, ν / cm–1) 
3077 (w), 3033 (w), 1609 (m), 1594 (s), 1569 (m), 1549 (m), 1544 (m), 1539 (m), 1531 
(m), 1464 (s), 1461 (s), 1456 (s), 1447 (m), 1432 (m), 1429 (m), 1423 (m), 1404 (m), 
1377 (m), 1373 (m), 1368 (m), 1247 (m), 1064 (m), 1028 (m), 999 (m), 995 (m), 895 (m), 
851 (m), 844 (m), 835 (s), 791 (m), 739 (m), 731 (m), 670 (m), 664 (m), 649 (m), 637 (s), 
629 (s), 619 (m), 616 (m), 604 (m), 597 (m), 582 (m), 570 (m), 564 (m), 543 (m), 541 
(m), 535 (m), 528 (m), 523 (m), 519 (m), 513 (s), 506 (s), 502 (s). UV-VIS (MeCN, 2.5 ×	
10–5 M) λ/nm (ε/ dm3 mol–1 cm–1) 247 (44458), 312 (7856). ESI-MS m/z 326.3 [M+H]+ 
(calc. 326.1). Found C 69.04, H 4.75, N 20.22; required for C20H15N5.H2O C 69.96, H 
4.99, N 20.40. 
 
2.4 [{ZnCl2(3)}n] 
A solution of ZnCl2 (3.41 mg, 0.025 mmol) in MeOH (8 mL) was layered over a CHCl3 
solution (5 mL) of 3 (7.78 mg, 0.025 mmol) and the tube was sealed with Parafilm. 
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Colourless crystals of [{ZnCl2(3)}n] (7.0 mg, 0.016 mmol, 63%) were obtained after 2 
weeks. IR (solid, ν / cm–1) 3062 (m), 1615 (s), 1607 (s), 1572 (m), 1559 (m), 1543 (m), 
1506 (m), 1447 (m), 1425 (m), 1396 (s), 1323 (m), 1218 (m), 1195 (m), 1135 (w), 1064 
(s), 1029 (s), 990 (w), 891 (w), 874 (m), 836 (s), 744 (w), 714 (s), 666 (w), 648 (s), 629 
(s), 514 (m). Found C 49.59, H 3.03, N 14.97; required for C19H13N5Cl2Zn.H2O C 49.01, 
H 3.25, N 15.04. 
 
2.5 [{ZnI2(3)}n] 
An MeOH (8 mL) solution of ZnI2 (8.0 mg, 0.025 mmol) was layered over a CHCl3 (5 
mL) solution of 3 (7.78 mg, 0.025 mmol). The tube was sealed with Parafilm and after 2 
weeks, yellow crystals of [{ZnI2(3)}n] (3.5 mg, 0.006 mmol, 22%) had grown. IR (solid, 
ν / cm–1) 3056 (w), 1614 (s), 1606 (s), 1568 (m), 1556 (m), 1506 (w), 1444 (m), 1421 
(m), 1396 (s), 1322 (w), 1220 (m), 1192 (w), 1135 (w), 1066 (s), 1025 (s), 991 (w), 886 
(w), 873 (w), 851 (m), 836 (s), 746 (w), 717 (m), 668 (w), 648 (s), 634 (s), 626 (s). Found 
C 35.60, H 2.27, N 10.89; required for C19H13I2N5I2Zn.H2O C 35.19, H 2.33, N 10.80. 
 
2.6 [{ZnI2(4).MeOH}n] 
A solution of ZnI2 (8.0 mg, 0.025 mmol) in MeOH (8 mL) was layered on top of a 
solution of 3 (4.07 mg, 0.013 mmol) in CHCl3(5 mL) and the tube was left sealed with 
Parafilm. Yellow crystals of [{ZnI2(4).MeOH}n] (8.0 mg, 0.012 mmol, 91%) were 
obtained after 2 weeks. IR (solid, ν / cm–1) 2922 (m), 1608 (s), 1548 (m), 1460 (s), 1406 
(m), 1372 (m), 1221 (w), 1065 (m), 1024 (s), 871 (w), 836 (s), 750 (w), 686 (m), 645 (s), 
630 (s), 599 (w), 505 (w). Found C 38.11, H 2.95, N 10.50; required for 
C20H15I2N5Zn.MeOH C 37.28, H 2.83, N 10.35. 
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2.7 Crystallography: general 
X-ray quality crystals of the complexes were selected from the bulk samples. Data were 
collected on a Bruker-Nonius Kappa APEX diffractometer; data reduction, solution and 
refinement used APEX2 [15] and SHELX13 [16]. The ORTEP plot was produced with 
Mercury v. 3.2 or 3.3 [17,18] which was also used for structure analysis. Crystallographic 
data are listed in Table 1.   
 
Table 1. Crystallographic data for compound 4 and the polymers [{ZnCl2(3)}n], 
[{ZnI2(3)}n] and [{ZnI2(4)].MeOH}n]. 
Compound 4  [{ZnCl2(3)}n]  [{ZnI2(3)}n]  [{ZnI2(4)].MeOH}n] 
Formula C20H15N5 C19H13Cl2N5Zn C19H13I2N5Zn C21H19I2N5OZn 
Formula weight 325.37 447.63 630.53 676.58 
Crystal colour and 
habit 
colourless block colourless needle yellow block yellow block 
Crystal system orthorhombic monoclinic monoclinic monoclinic 
Space group Pmn21 P21/n P21/n P21/n 
a, b, c / Å 18.0817(12) 
4.3834(3) 
9.7540(6) 
8.4559(11) 
19.194(2) 
11.2787(13) 
10.0386(7) 
11.2543(8) 
18.3065(13) 
11.3508(4) 
11.6668(4) 
17.6152(6) 
α, β, γ / o 90 
90 
90 
90 
97.057(9) 
90 
90 
103.838(3) 
90 
90 
103.204(2) 
90 
U / Å3 773.10(9) 1816.6(4) 2008.2(2) 2271.07(14) 
Dc / Mg m–3 1.398 1.637 2.085 1.979 
T / K 123 123 123 123 
Z 2 4 4 4 
µ(Cu-Kα) / mm–1 0.691 4.701 25.948 23.030 
Refln. collected (Rint) 9665 (0.0295) 15849 (0.0643) 36476 (0.0436) 33192 (0.0387) 
Unique refln. 1449 3260 3628 4126 
Refln. for refinement 1429 2331 3516 3891 
Parameters 121 281 244 274 
Threshold I >2σ (I) I >2σ (I) I >2σ (I) I >2σ (I) 
R1 (R1 all data) 0.0262 (0.0265) 0.0528 (0.0795) 0.0272 (0.0283) 0.0222 (0.0237) 
wR2 (wR2 all data) 0.0731 (0.0736) 0.1330 (0.1473) 0.0710 (0.0718) 0.0578 (0.0588) 
Goodness of fit 1.088 1.015 1.104 1.035 
  
3 Results and discussion 
3.1 Synthesis and characterization of compounds 3 and 4. 
Compounds 3 and 4 were synthesized using the one-pot strategy introduced by Hanan 
[19] and were isolated in 51 and 32% yields, respectively. The electrospray mass 
spectrum of 3 and 4 showed base peaks at m/z = 312.2 and 326.3, respectively, arising 
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from [M+H]+ ions. Satisfactory elemental analytical data for 3 could not be obtained, 
despite repeated recrystallizations of the bulk material from MeOH/CHCl3. The 1H NMR 
spectrum of a CDCl3 solution of 3 was assigned using NOESY with observations of cross 
peaks between signals for HC4/HB3 and HA3/HB3. However, the poor solubility of 3 in 
CDCl3 (and also in CD2Cl2, CD3CN, CD3OD and d6-DMSO) did not permit the 13C NMR 
spectrum to be resolved, despite the use of HMQC and HMBC methods. Thus, the 1H and 
13C NMR spectra of the protonated ligand were recorded in d-TFA and were assigned by 
2D methods (COSY, HMQC, HMBC and NOESY). The shifting of all 1H NMR signals 
to higher frequency on going from CDCl3 to d-TFA is consistent with multiple 
protonation of 3 in TFA Introduction of the 2-methyl-substituent on going from 3 to 4 
improves the solubility in CDCl3.   
 The absorption spectra of CH2Cl2 solutions (2.5 ×	10–5 mol dm–3) of both 3 and 4 
are similar. Intense, high energy bands (λmax = 242 nm for 3 and 247 for 4) and a lower 
intensity absorption at 312 nm in both compounds were assigned to π*←π and π*←n 
transitions.  
 X-ray quality single crystals of 4 were grown serendipitously during attempts to 
react 4 with iron(II) perchlorate in MeOH; Figure 1 depicts the molecular structure of 4. 
The compound crystallizes in the orthorhombic Pmn21 space group with half the 
molecular in the asymmetric unit; the second half is generated by a mirror plane.  Bond 
distances and angles (caption to figure 1) are as expected. The planes containing pyridine 
rings with N1 and N2 lie at 4.5o with respect to each other, and essentially, the molecule 
is planar. Molecules of 4 engage in face-to-face π-interactions. Adjacent molecules are 
slipped with respect to one another leading to the dominant interaction being between 
central pyridine and pyrimidine rings (Figure 2a, distance between planes = 3.32 Å; inter-
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centroid separation = 3.63 Å). The stacks assemble in a herring-bone arrangement with 
CH...N hydrogen bonds as the dominant packing interactions (C10H10a...N1ii = 2.52, 
C4H4a...N1ii = 2.66, C7H7a...N1ii = 2.74, N3...H5aiiiC5iii = 2.52 Å, symmetry codes: ii = 
3/2–x, 1–y, –1/2+z; iii = 3/2–x, 2–y, 1/2+z). 
 
 
Fig. 1. Structure of molecule 4 with ellipsoids plotted at the 40% probability level. 
Symmetry code i = 2–x, y, z. Selected bond parameters: N1–C5 = 1.335(2), N1–C1 = 
1.337(2), N2–C6 = 1.3402(19), N3–C10 = 1.336(2), N3–C11 = 1.3395(17) Å; C5–N1–
C1 = 116.12(15), C6–N2–C6i = 118.19(19), C10–N3–C11 = 116.69(14)o. 
 
   
Fig. 2 Packing of molecules of 4 in the crystal lattice showing π-stacking of planar 
molecules and herring-bone arrangement of the stacks. 
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3.2 Reaction of 3 with ZnCl2 
Layering solutions of MeOH/ZnCl2 and CHCl3/3 resulted in the growth of colourless 
crystals. Elemental analysis of the bulk sample was consistent with a stoichiometry 
ZnCl2(3) and single crystal X-ray analysis confirmed the formation of the 1-dimensional 
coordination polymer [{ZnCl2(3)}n]. The complex crystallizes in the monoclinic space 
group P21/n with one {ZnCl2(3)} unit in the asymmetric unit. The pyrimidin-5-yl 
substituent is disordered and has been modelled over two sites (0.61 and 0.39 fractional 
occupancies) both having atoms C17 and C19 in common. Only the major occupancy site 
is shown in Figure 3. The rings containing N1, N2 and N3 are essentially coplanar 
(angles between the planes containing N1/N2 and N2/N3 = 1.8  and 5.3o, respectively); 
for the major occupancy site, the plane of the pyrimidine ring is twisted 19.8o with 
respect to the ring containing N3. Atom Zn1 is in a distorted tetrahedral environment and 
ligand 3 bridges through the outer pyridine rings (N1 and N3) between pairs of 
ZnCl2units. As is characteristic of 4,2':6',4''-tpy ligands [1], the central donor N2 is not 
coordinated. Atoms N4 and N5 in the pyrimidine ring are also non-coordinating. In this 
respect, the structure can be compared with that of the 1-dimensional polymer [{ZnCl2(4'-
(4-pyridyl)-4,2':6',4''-tpy)}n] [20] in which the pendant pyridyl domain does not 
coordinate. The structures of [{ZnCl2(3)}n] and [{ZnCl2(4'-(4-pyridyl)-4,2':6',4''-tpy)}n] 
are also similar in that the polymer chains are both built up by 2-fold screw axes. That 3 
bridges through two pyridyl donors of the 4,2':6',4''-tpy domain contrasts with the related 
ligand 2 (Scheme 1) which can bridge through one pyridyl donor and one pyrimidinyl 
unit [14]. The pitch of the helical [{ZnCl2(3)}n] chain (19.194(2) Å) is related to the N–
Zn–N angle [1] and the value of 107.15(15)o) in [{ZnCl2(3)}n] is similar to that in 
[{ZnCl2(4'-(4-pyridyl)-4,2':6',4''-tpy)}n] (108.3(1)o) in which the helical pitch is 20.661(3) 
Å [20].  
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Fig. 3  Repeat unit (showing connectivities to the next units) in [{ZnCl2(3)}n]; symmetry 
codes: i = 1/2–x, –1/2+y, 3/2–z; ii = 1/2–x, 1/2+y, 3/2–z) and ellipsoids plotted at the 40% 
probability level. Selected bond parameters: Zn1–N1 = 2.046(3), Zn1–N3ii = 2.054(4), 
Zn1–Cl2 = 2.1996(15), Zn1–Cl1 = 2.2384(17) Å; N1–Zn1–N3ii = 107.15(15), N1–Zn1–
Cl2 = 111.25(12), N3ii–Zn1–Cl2 = 110.22(11), N1–Zn1–Cl1 = 103.37(12), N3ii–Zn1–Cl1 
= 101.46(12), Cl2–Zn1–Cl1 = 122.15(8)o. 
  
 Both the P- and M-helices are present in the lattice of [{ZnCl2(3)}n] and chains of 
opposite chirality associate through face-to-face π-interactions of 4,2':6',4''-tpy units. 
Figure 4 shows that this involves discrete tetradecker domains. At the centre of the 
sandwich, the rings containing N1 and N2 of a centrosymmetric pair of 4,2':6',4''-tpy 
units stack with an interplane separation of  3.35 Å. The outer π-interactions involve 
stacking of the ring with N3 over the pair of rings with N1/N2. The interactions between 
P- and M-chains is closely related to that observed in [{ZnCl2(4'-(4-pyridyl)-4,2':6',4''-
tpy)}n] [1,20]. 
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Fig. 4  Packing of P- and M-chains in [{ZnCl2(3)}n] involves discrete tetradecker π-
stacking domains involving 4,2':6',4''-tpy units. Chains of opposite chirality are shown in 
red and blue, respectively. 
 
3.3 Reactions of 3 and 4 with ZnI2.  
Layering experiments with an MeOH solution of ZnI2 and CHCl3 solution of 3 or 4 
resulted in the formation of yellow crystals of the 1-dimensional coordination polymers 
[{ZnI2(3)}n] and [{ZnI2(4).MeOH}n], respectively. Despite the presence of solvent 
molecules in the latter, the two structures are very similar and will be discussed together. 
Both complexes crystallize in the monoclinic space group P21/n and Figure 5 depicts the 
repeat unit in [{ZnI2(4).MeOH}n]. The same numbering scheme for both compounds has 
been used and a comparison of important bond parameters is given in Table 2. The 
tetrahedral coordination environment of Zn1 in each complex is similarly distorted, as 
indicated by the N–Zn–N and I–Zn–I bond angles (Table 2). Figure 5 includes the 
MeOH molecule which forms an O–H...N hydrogen bond with the pyrimidinyl unit 
(O100H100...N5 = 2.03, O100...N5 = 2.856(3) Å, O100–H100...N5 = 169o). Its presence 
in the lattice is associated with an enlarged cavity which results from the replacement of 
the hydrogen atom attached to C19 in 3 by the methyl group in 4. The pyridine and 
pyrimidine rings are twisted with respect to one another in both [ZnI2(3)]n and 
[{ZnI2(4).MeOH}n] with twist angles in the range 17.2 to 39.7o.  
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Fig. 5 Repeat unit (showing connectivities to the next units) in [{ZnI2(4).MeOH}n]; 
symmetry codes: i = –1/2+x, 1/2–y,  –1/2+z; ii = 1/2+x, 1/2–y, 1/2+z) and ellipsoids plotted at 
the 40% probability level.  
 
 
 
 
 
Table 2 Comparison of selected bond parameters in [{ZnI2(3)}n] and 
[{ZnI2(4).MeOH}n]. The atom numbering for both complexes is as given in Figure 5.  
Bond distance / Å  [{ZnI2(3)}n]a [{ZnI2(4).MeOH}n] b 
Zn–N1 2.065(3) 2.076(2) 
Zn1–N3ii 2.066(3) 2.066(2) 
Zn1–I1 2.5376(5) 2.5530(4) 
Zn1–I2 2.5324(5) 2.5426(4) 
   
Bond angle / deg   
N1–Zn1–N3ii 95.54(12) 96.60(9) 
I2–Zn1–I1 119.041(19) 123.725(15) 
a Symmetry code: ii = 1/2+x, 1/2–y, 1/2+z. 
a Symmetry code: ii = –1/2+x, 1/2–y, –1/2+z. 
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As in [{ZnCl2(3)}n], only the outer pyridine rings of the 4,2':6',4''-tpy domains in 
[{ZnI2(3)}n] and [{ZnI2(4).MeOH}n] bind to zinc(II). In both compounds, the polymer 
chain is built up along a glide plane, leading to non-helical polymer chains in contrast to 
that in [{ZnCl2(3)}n]. The Zn...Zn separations between pairs of adjacent Zn atoms long 
the chain are 12.9298(9) Å in [{ZnI2(3)}n] and 13.0295(6) Å in [{ZnI2(4).MeOH}n]. 
 Chains in [{ZnI2(3)}n] interact with one another through π-interactions between 
4,2':6',4''-tpy domains as shown in Figure 6a. This results in the assembly of sheets which 
slice obliquely through the unit cell (Figure 6b). The pyrimidin-5-yl domains project from 
each side of the sheet and assist in locking the sheets together in the lattice. Similar 
packing motifs are present in [{ZnI2(4).MeOH}n].  
 
    
(a)       (b) 
 
Figure 6.  Assembly of sheets of chains in [{ZnI2(3)}n]. (a) View down the a-axis to 
emphasize the face-to-face π-interactions between chains, and (b) view down the b-axis 
showing the protruding pyrimidin-5-yl domains on each side of the sheet. 
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3.4 Solution absorption spectra of the coordination polymers 
 
The absorption spectra of MeCN solutions of dissolved crystalline [{ZnCl2(3)}n] and 
[{ZnI2(3)}n] both showed a broad maximum at 242 nm with a lower energy shoulder at 
≈310 nm. The spectra are very similar to that of an MeCN solution of free ligand 3. The 
absorption spectra of MeCN solutions of [{ZnI2(4)}n] and 4 both exhibit the same band 
maxima at 247 and 312 nm. The data are consistent with dissociation of the complexes in 
MeCN solution, thus precluding further solution characterization of the materials.  
 
4 Conclusions 
 We have described the preparation and characterization of two new 4'-functionalized 
4,2':6',4''-tpy ligands bearing pendant pyrimidin-5-yl or 2-methylpyrimidin-5-yl 
substituents. In reactions with ZnCl2 and ZnI2, the ligands bind only through the outer 
pyridine donors and form 1-dimensional coordination polymers [{ZnCl2(3)}n], 
[{ZnI2(3)}n] and [{ZnI2(4).MeOH}n]. [{ZnCl2(3)}n] is helical and crystallizes as a 
racemate; it is structurally similar to the previously reported [{ZnCl2(4'-(4-pyridyl)-
4,2':6',4''-tpy)}n] [20]. In contrast, the chains in [{ZnI2(3)}n] and [{ZnI2(4).MeOH}n] are 
built up by glide planes. The two compounds are structurally analogous, and chains pack 
into sheets through π-interactions between 4,2':6',4''-tpy domains; the pyrimidin-5-yl units 
protrude from the sheets and are involved in interlocking the latter into a 3D assembly. 
Introducing the 2-methyl substituent on going from 3 to 4 pushes the sheets apart slightly, 
resulting in MeOH solvent molecules being accommodated in cavities between the 
layers.  
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Appendix 1 Supplementary data      
Crystallographic data have been deposited with the CCDC (Cambridge Crystallographic 
Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax +44 1223 336033; e-mail: 
deposit@ccdc.cam.ac.uk or www: http://www.ccdc.cam.ac.uk) and may be obtained free 
of charge on quoting the deposition numbers CCDC 996287–996290. 
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